Nasdaq Hearings Panel Granted Alzamend's Request To Continue Its Listing, Subject To Alzamend Demonstrating Compliance, On Or Before September 23, 2024
Portfolio Pulse from Benzinga Newsdesk
Alzamend Neuro, Inc. (NASDAQ:ALZN) has been granted an extension by the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market. The company must demonstrate compliance with the stockholder equity requirement of at least $2.5 million by September 23, 2024.
May 22, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alzamend Neuro has been granted an extension by the Nasdaq Hearings Panel to continue its listing, provided it meets the stockholder equity requirement of $2.5 million by September 23, 2024.
The extension allows Alzamend Neuro more time to meet the Nasdaq's stockholder equity requirement, which is positive news for the company's stock as it avoids immediate delisting. This should provide short-term stability and potentially boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100